Lenka Fedorkova, PhD
Lenka Fedorkova, PhD, is the Vice President of Business Development and Strategic Alliance Management for the Harrington Discovery Institute (HDI).
Lenka is an accomplished health care innovation executive and is responsible for identifying and developing commercial opportunities that are aligned with the organization’s mission and portfolio. In her role she supports HDI’s growing international footprint and serves as lead evangelist for showcasing HDI’s value proposition to both commercial and academic partners. Lenka is also responsible for developing long-range strategic partnership opportunities with pharma, non-profit and academic stakeholders toward translating HDI’s strategy into tactical plans to achieve its goals and objectives.
Prior to joining HDI in 2020, Lenka was Chief Executive Officer and Founder of bioPrime, LLC, a professional advisory services firm dedicated to helping accelerate health care and biomedical innovations from the idea stage toward market readiness and commercial viability. At bioPrime she raised funding for early-stage biotechnology company clients across the US, coached and mentored hundreds of entrepreneurs across a wide range of life science technologies. Preceding her work in the private sector, Lenka was the Executive Manager for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health (NIH). There she managed a large-scale SBIR/STTR program portfolio ($780 M budget) across the agency as well as the Food and Drug Administration (FDA) and the Centers for Disease Control (CDC), which together comprise the world’s largest source of life sciences innovation pipeline and early-stage, non-dilutive seed funding.
Lenka obtained her PhD in Neuroscience from the Kent State University, Ohio and received the prestigious AAAS Science and Technology Policy Fellowship at NIH’s Office of Technology Transfer, where she was an active member involved in evaluation and licensing of NIH inventions to the bio-pharmaceutical sector.